Literature DB >> 28306621

Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.

Seong Young Kwon1, Eun Kyoung Choi, Eun Jung Kong, Ari Chong, Jung-Min Ha, Kyung Ah Chun, Ihn Ho Cho, Hee-Seung Bom, Jung-Joon Min, Jahae Kim, Ho-Chun Song, Joo Hyun O, Sung Hoon Kim.   

Abstract

OBJECTIVE: Metastatic lymph node ratio (MLNR) is a known significant predictor of disease-free survival in differentiated thyroid cancer. The authors investigated the ability of preoperative fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT to predict recurrence after surgery with radioactive iodine therapy considering MLNR. PATIENTS AND METHODS: A total of 274 patients who underwent preoperative PET/CT and surgery with radioactive iodine therapy were enrolled. The tumor-to-liver uptake ratio on PET/CT was calculated by dividing the maximum standardized uptake value of a primary lesion by the mean standardized uptake value of the normal liver. High F-FDG uptake was defined as tumor-to-liver uptake ratio more than the median cutoff value (2.1). MLNR was calculated by dividing the number of metastatic lymph nodes (LNs) by the number of cervical LNs removed. A high MLNR was also defined as one more than a threshold value (0.4), identified by plotting Kaplan-Meier survival curves and comparing them using the log-rank test. The prognostic significances of clinicopathologic variables were analyzed.
RESULTS: Fifteen (5.5%) patients developed recurrence in the thyroid bed or in cervical LNs. Cox regression analysis showed that a high MLNR was significantly associated with a worse disease-free survival (odds ratio 6.95; 95% confidence interval: 2.36-20.47; P<0.001). A subgroup analysis of 70 patients with a high MLNR showed that only high F-FDG uptake was significantly associated with a worse disease-free survival (odds ratio 5.77; 95% confidence interval: 1.22-27.16; P=0.027).
CONCLUSION: High F-FDG uptake of primary lesion on preoperative PET/CT has selective prognostic value according to the extent of metastatic LNs (MLNR>0.4).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28306621     DOI: 10.1097/MNM.0000000000000657

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

Review 2.  KSNM60 in Nuclear Endocrinology: from the Beginning to the Future.

Authors:  Chae Moon Hong; Young Jin Jeong; Hae Won Kim; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2022-01-24

3.  Assessment of incidental focal colorectal uptake by analysis of fluorine-18 fluorodeoxyglucose positron emission tomography parameters.

Authors:  Haejun Lee; Kyung-Hoon Hwang; Kwang An Kwon
Journal:  World J Clin Cases       Date:  2022-06-16       Impact factor: 1.534

4.  Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review.

Authors:  Hongxi Wang; Hongyuan Dai; Qianrui Li; Guohua Shen; Lei Shi; Rong Tian
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

5.  Risk factors of malignant fluorodeoxyglucose-avid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy.

Authors:  Sang-Geon Cho; Seong Young Kwon; Jahae Kim; Dong-Hyeok Cho; Myung Hwan Na; Sae-Ryung Kang; Su Woong Yoo; Ho-Chun Song
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.